Immunomedics: mAb massing method buffers against biosimilars
Immunomedics claims a new concentration technique has protected its portfolio of candidate mAb cancer drugs from biosimilar competition for longer.
Archives for March 4, 2014
Proteomics teams with inVentiv for biosimilar, biologics development
Proteomics International has agreed to collaborate with inVentiv Health to develop biosimilars and biologics, which will begin with structural and functional characterization.
Demand for plasmid production growing says Cobra Biologics
Cobra Biologics is looking for more scientists with plasmid production skills after BioCancell became the fifth firm in a year to ask the CMO to manufacture a DNA-based gene therapy candidate.
US FDA outlines new data requirements for HIV vaccine developers
The US FDA outlined in draft guidance the ways in which sponsors must submit data for their HIV vaccines and other treatments.